<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="iso-abbrev">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="publisher-id">An Bras Dermatol</journal-id>
      <journal-title-group>
        <journal-title>Anais Brasileiros de Dermatologia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0365-0596</issn>
      <issn pub-type="epub">1806-4841</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Dermatologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">24068143</article-id>
      <article-id pub-id-type="pmc">3760947</article-id>
      <article-id pub-id-type="doi">10.1590/abd1806-4841.20131990</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Severe Multi-Resistant Pemphigus vulgaris: prolonged remission with a
single cycle of Rituximab<xref ref-type="fn" rid="fn01">*</xref></article-title>
        <trans-title-group xml:lang="pt">
          <trans-title>P&#xEA;nfigo vulgar grave Multirresistente: controle prolongado com um &#xFA;nico
ciclo de Rituximabe</trans-title>
        </trans-title-group>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Corral</surname>
            <given-names>Isabela Soubhia</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
          <xref ref-type="corresp" rid="c01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>de Freitas</surname>
            <given-names>Thais Helena Proen&#xE7;a</given-names>
          </name>
          <xref ref-type="aff" rid="aff02">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>de Aquino</surname>
            <given-names>Renata Telles Rudge</given-names>
          </name>
          <xref ref-type="aff" rid="aff03">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Koller</surname>
            <given-names>Daniella Abbruzzini S.</given-names>
          </name>
          <xref ref-type="aff" rid="aff04">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Magliari</surname>
            <given-names>Maria Elisa Ruffolo</given-names>
          </name>
          <xref ref-type="aff" rid="aff05">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Muller</surname>
            <given-names>Helena</given-names>
          </name>
          <xref ref-type="aff" rid="aff06">6</xref>
        </contrib>
      </contrib-group>
      <aff id="aff01"><label>1</label> Dermatologist - MD at the Dermatology Clinic at Santa Casa de
Miseric&#xF3;rdia de S&#xE3;o Paulo - S&#xE3;o Paulo (SP), Brazil.</aff>
      <aff id="aff02"><label>2</label> MD, MSc in Dermatology at the Federal University of S&#xE3;o Paulo
(UNIFESP). Voluntary physician at the Dermatology Clinic at Santa Casa de Miseric&#xF3;rdia
de S&#xE3;o Paulo - S&#xE3;o Paulo (SP), Brazil.</aff>
      <aff id="aff03"><label>3</label> MD, PhD in general medicine at the Faculdade de Ci&#xEA;ncias M&#xE9;dicas da
Santa Casa de Miseric&#xF3;rdia de S&#xE3;o Paulo (FCMSCMSP) - Voluntary physician at the Medicine
Department at the Faculdade de Ci&#xEA;ncias M&#xE9;dicas da Santa Casa de Miseric&#xF3;rdia de S&#xE3;o
Paulo (FCMSCMSP) - S&#xE3;o Paulo (SP), Brazil.</aff>
      <aff id="aff04"><label>4</label> Dermatologist - MD, voluntary physician at the Dermatology Clinic at
Santa Casa de Miseric&#xF3;rdia de S&#xE3;o Paulo - S&#xE3;o Paulo (SP), Brazil.</aff>
      <aff id="aff05"><label>5</label> MD, MSc in General Medicine at the Medicine Department at the Faculdade
de Ci&#xEA;ncias M&#xE9;dicas da Santa Casa de Miseric&#xF3;rdia de S&#xE3;o Paulo (FCMSCMSP) - Professor of
general medicine at the Medicine Department at the Faculdade de Ci&#xEA;ncias M&#xE9;dicas da
Santa Casa de Miseric&#xF3;rdia de S&#xE3;o Paulo (FCMSCMSP) - S&#xE3;o Paulo (SP), Brazil.</aff>
      <aff id="aff06"><label>6</label> Pathologist MD, Assistant Professor at the Pathological Sciences
Department at the Faculdade de Ci&#xEA;ncias M&#xE9;dicas da Santa Casa de Miseric&#xF3;rdia de S&#xE3;o
Paulo (FCMSCSP) - S&#xE3;o Paulo (SP), Brazil.</aff>
      <author-notes>
        <corresp id="c01"><bold>MAILING ADDRESS:</bold> Isabela Soubhia Corral, Rua Dr. Ces&#xE1;rio
Motta Jr, 112 - Vila Buarque, 01221-020 - S&#xE3;o Paulo - SP, Brazil, E-mail:
<email>isa_corral@hotmail.com</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <season>Jul-Aug</season>
        <year>2013</year>
      </pub-date>
      <volume>88</volume>
      <issue>4</issue>
      <fpage>639</fpage>
      <lpage>642</lpage>
      <history>
        <date date-type="received">
          <day>16</day>
          <month>7</month>
          <year>2012</year>
        </date>
        <date date-type="accepted">
          <day>30</day>
          <month>8</month>
          <year>2012</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9;2013 by Anais Brasileiros de Dermatologia</copyright-statement>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
          <license-p>This is an open-access article distributed under the terms of the Creative
Commons Attribution License, which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly
cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Pemphigus vulgaris is an autoimmune bullous disease whose therapy is based on
systemic corticosteroids, with or without immunosuppressants. Rituximab is a chimeric
monoclonal antibody of the IgG class, directed at a specific CD20 B cell surface
antigen, used in pemphigus vulgaris empirically since 2002, with success in 90% of
the cases and long periods of remission. Male patient, 33 years old, diagnosed with
pemphigus vulgaris, confirmed by histopathology and direct immunofluorescence. He was
treated for seven months with numerous treatments, including immunosuppressive drugs,
with an unsatisfactory response, until he had complete remission with the use of
rituximab. During a 34-month follow-up period, the patient presented a slight
clinical relapse, which was successfully controlled with prednisone in a daily dose
of 120mg, soon reduced to 20mg.</p>
      </abstract>
      <trans-abstract xml:lang="pt">
        <p>P&#xEA;nfigo Vulgar &#xE9; uma doen&#xE7;a bolhosa auto-imune, cuja terap&#xEA;utica &#xE9; baseada em
corticoester&#xF3;ides sist&#xEA;micos, associados ou n&#xE3;o a imunossupressores. Rituximabe &#xE9; um
anticorpo monoclonal quim&#xE9;rico da classe IgG direcionado a um ant&#xED;geno CD20 de
superf&#xED;cie celular espec&#xED;fico da c&#xE9;lula B, usado em p&#xEA;nfigo vulgar desde 2002, com
sucesso em 90% e longos per&#xED;odos de remiss&#xE3;o. Paciente masculino, 33 anos,
diagn&#xF3;stico de p&#xEA;nfigo vulgar, confirmado por histopatologia e imunofluoresc&#xEA;ncia
direta. Durante 7 meses, recebeu in&#xFA;meros tratamentos com imunossupressores,
apresentando resposta insatisfat&#xF3;ria e progress&#xE3;o da doen&#xE7;a, at&#xE9; que logo ap&#xF3;s a
introdu&#xE7;&#xE3;o de rituximabe teve completa remiss&#xE3;o. Durante um acompanhamento de 34
meses, apresentou leve recidiva cl&#xED;nica, controlada com prednisona 120mg/dia,
rapidamente reduzida e em uso atual de Prednisona 20mg/dia.</p>
      </trans-abstract>
      <kwd-group>
        <kwd>Desmogleins</kwd>
        <kwd>Drug resistance</kwd>
        <kwd>Pemphigus</kwd>
        <kwd>Treatment failure</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>INTRODUCTION</title>
      <p>Pemphigus vulgaris is an autoimmune bullous, potentially life-threatening disease,
characterized by the presence of autoantibodies against desmosomal cadherins such as
desmogleins 1 and 3. Therapeutic strategies rely on the use of systemic corticosteroids
alone or in conjunction with other immunosuppressant drugs such as azathioprine,
mycophenolate mofetil, methotrexate, cyclophosphamide or immunomodulators like dapsone
or intravenous immunoglobulin.<sup><xref ref-type="bibr" rid="B01">1</xref>,<xref ref-type="bibr" rid="B02">2</xref></sup>
</p>
      <p>Rituximab is a chimeric monoclonal antibody of the IgG class, directed at a specific
CD20 B-cell surface antigen. The effect of the drug on B-cell depletion stimulated its
widespread use in a great variety of autoimmune diseases. In 1997, it was approved by
the FDA for use in the treatment of non-Hodgkin's lymphomas and autoimmune diseases such
as rheumatoid arthritis. In 1998, Anvisa approved rituximab for the same
indications.<sup><xref ref-type="bibr" rid="B01">1</xref>-<xref ref-type="bibr" rid="B05">5</xref></sup> The first report of rituximab in the treatment of
pemphigus was publish in 2002 and many studies since have shown favorable results,
specially in patients that did not respond to classic or conventional treatments
previously.<sup><xref ref-type="bibr" rid="B03">3</xref></sup>
</p>
      <p>The drug links to the CD20 receptors, expressed on the auto-reactive B-lymphocytes
membranes, resulting in their destruction, with subsequent diminished anti-desmoglein
autoantibodies production. In cases in which relapse occur, a new increase in the level
of such antibodies was demonstrated.<sup><xref ref-type="bibr" rid="B05">5</xref></sup>
</p>
    </sec>
    <sec>
      <title>CASE REPORT</title>
      <p>Male patient, 33 years-old, without any morbid antecedents of notice, was admitted to
the hospital with a history of painful bullous lesions on the scalp and oral cavity
since two months before, with subsequent dissemination to the entire body. Physical
examination showed flaccid blisters, mostly with serous content, besides exulcerated
lesions covered in honey-colored crusts. (<xref ref-type="fig" rid="f01">Figure
1</xref>) The diagnostic hypothesis was pemphigus vulgaris, later confirmed by skin
biopsies and direct immunofluorescence. Treatment with prednisone 1mg/Kg/day and
antibiotics to address the secondary infection was then started. The patient was
released 15 days later, with a slightly improved clinical condition.</p>
      <fig id="f01" fig-type="other" orientation="portrait" position="float">
        <label>FIGURE 1</label>
        <caption>
          <p>01/05/2009 &#x2013; Before rituximab</p>
        </caption>
        <graphic xlink:href="abd-88-0639-g01"/>
      </fig>
      <p>He returned 10 days later, due to the appearance of new blisters, worsening of the pain
and odynophagia. The dose of corticoid was increased to 1.5mg/Kg/day, and both sulfone
100 mg/day and systemic antibiotics were added to the treatment. As the patient's
clinical condition rapidly deteriorated, sulfone was replaced by azathioprine 150 mg/day
and the dose of prednisone was once again increased to 2mg/Kg/day. Despite these
actions, there was a decline in the patient's general condition, and a worsening of the
cutaneous lesions, accompanied by the development of thrombocytopenia secondary to the
use of azathioprine. In a period of 20 days, the patient had almost 100% of his body
surface stricken by the disease, including all mucosae (oral, nasal, ocular, penile,
anal) and the periungual regions of all fingers and toes. He was then submitted to
intravenous methylprednisolone pulse therapy in a dose of 1g/day for 5 days. A week
after the pulse therapy, new lesions were still appearing, leading to the introduction
of five cycles of intravenous immunoglobulin at 400mg/Kg/per cycle. After 75 days of
hospitalization, the patient was discharged with an improved clinical condition.</p>
      <p>One month after being discharged, the patient had a clinical relapse, with the
appearance of new bullous lesions despite the daily use of prednisone 2mg/Kg. A new
cycle of intravenous immunoglobulin was performed, followed by a second pulse therapy
with methylprednisolone and the addition of mycophenolate mofetil 3g/day for 30 days.
However, mycophenolate mofetil was suspended due to Kaposi varicelliform eruptions,
which were treated with intravenous acyclovir (<xref ref-type="fig" rid="f02">Figure
2</xref>).</p>
      <fig id="f02" fig-type="other" orientation="portrait" position="float">
        <label>FIGURE 2</label>
        <caption>
          <p>10/09/2009 &#x2013; Kaposi varicelliform eruption</p>
        </caption>
        <graphic xlink:href="abd-88-0639-g02"/>
      </fig>
      <p>The persisting lack of clinical response resulted in the use of cyclophosphamide pulse
therapy at 250mg/day, associated to dexamethasone 100 mg/day for 3 days. As the patient
was still unresponsive, weekly intravenous treatment with rituximab 375mg/m2 (4 cycles)
was started. The patient presented with improvement of the cutaneous lesions after the
first cycle and a complete remission in 20 days, being discharged with a prescription of
prednisone 2 mg/Kg/day and cyclophosphamide 50 mg/day (<xref ref-type="fig" rid="f03">Figure 3</xref>). These medications were progressively withdrawn and the patient was
asymptomatic for 23 months using only low dosage corticoids (5mg/day). After this period
there was a slight clinical relapse, which was controlled with prednisone 120 mg/day,
resulting in rapid regression of the disease. Presently, after 34 months of follow-up,
the patient is being treated only with prednisone 20 mg/day (<xref ref-type="fig" rid="f04">Figure 4</xref>).</p>
      <fig id="f03" fig-type="other" orientation="portrait" position="float">
        <label>FIGURE 3</label>
        <caption>
          <p>03/02/2010- 3 months after rituximab</p>
        </caption>
        <graphic xlink:href="abd-88-0639-g03"/>
      </fig>
      <fig id="f04" fig-type="other" orientation="portrait" position="float">
        <label>FIGURE 4</label>
        <caption>
          <p>20/07/2012 &#x2013; 34 months after rituximab</p>
        </caption>
        <graphic xlink:href="abd-88-0639-g04"/>
      </fig>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>It has already been demonstrated that, rituximab - an anti-CD20 monoclonal antibody
-induces a rapid and specific B-lymphocyte CD20+ peripheric depletion, thus acting on
the main effector pathway of pemphigus vulgaris (pathogenic antibodies produced by B
cells), without causing unspecific immunosuppressive responses, as observed with
conventional therapy (systemic corticoids and other immunosuppressants). Furthermore,
treatment with rituximab leads to a rapid decline in the plasma levels of IgG4
anti-desmoglein-3 and anti-desmoglein-1, which correlates directly with clinical
remission.<sup><xref ref-type="bibr" rid="B01">1</xref>-<xref ref-type="bibr" rid="B06">6</xref></sup>
</p>
      <p>First used on a bullous pemphigoid associated to non-Hodgkin's lymphoma in 1999, this
drug was proven to be effective on pemphigus vulgaris, inducing long remissions and high
rates of partial or total response (90-95%). It has become a therapeutic alternative for
patients that are refractory to conventional treatments or those presenting with severe
adverse events secondary to systemic corticoids or immunosuppressants, and thus far, due
to its high costs and lack of evidence on long-term effects, rituximab should be
reserved only for such patients. However, Hertl et al. discussed the possibility that
rituximab might become the drug of choice in the treatment of generalized pemphigus,
since the long-term remissions would minimize the impact of its high costs on the
healthcare budget. In the case reported here, the early use of rituximab might have
diminished the hospitalization time, which was 7 months in total, and also mitigated the
various complications secondary to the use of corticoids and
immunosuppressants.<sup><xref ref-type="bibr" rid="B02">2</xref>,<xref ref-type="bibr" rid="B07">7</xref>-<xref ref-type="bibr" rid="B10">10</xref></sup>
</p>
      <p>Rituximab has a good safety profile up to 3 years of follow-up, and its adverse events
are mostly mild and transitory: nausea, vomiting, chills, urticaria and cough. Severe
adverse events are rare, with opportunistic infections being the main risk. The effect
of rituximab on the levels of antibodies related to immunization, particularly in
younger patients, may be minimized with concomitant use of intravenous immunoglobulin,
thus reducing the risk of infections.<sup><xref ref-type="bibr" rid="B01">1</xref>,<xref ref-type="bibr" rid="B06">6</xref>,<xref ref-type="bibr" rid="B07">7</xref>,<xref ref-type="bibr" rid="B08">8</xref></sup></p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn id="fn01" fn-type="other">
        <label>*</label>
        <p>Work performed at the Medicine Department and Dermatology Clinic at the Santa Casa de
Miseric&#xF3;rdia de S&#xE3;o Paulo - S&#xE3;o Paulo (SP), Brazil.</p>
      </fn>
      <fn id="fn02" fn-type="conflict">
        <p>Conflict of interest: None</p>
      </fn>
      <fn id="fn03" fn-type="financial-disclosure">
        <p>Financial funding: None</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="B01">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hertl</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Zillikens</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Borradori</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Bruckner-Tuderman</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Burckhard</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Eming</surname>
              <given-names>R</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Recommendations for the use of rituximab (anti-CD20 antibody) in the
treatment of autoimmune bullous skin diseases</article-title>
          <source>J Dtsch Dermatol Ges</source>
          <year>2008</year>
          <volume>6</volume>
          <fpage>366</fpage>
          <lpage>373</lpage>
          <pub-id pub-id-type="pmid">18201220</pub-id>
        </element-citation>
      </ref>
      <ref id="B02">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Goebeler</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Herzog</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Br&#xF6;cker</surname>
              <given-names>EB</given-names>
            </name>
            <name>
              <surname>Zillikens</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Rapid response of treatment-resistant pemphigus foliaceus to the
anti-CD20 antibody rituximab</article-title>
          <source>Br J Dermatol</source>
          <year>2003</year>
          <volume>149</volume>
          <fpage>899</fpage>
          <lpage>901</lpage>
          <pub-id pub-id-type="pmid">14616397</pub-id>
        </element-citation>
      </ref>
      <ref id="B03">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Daniel</surname>
              <given-names>BS</given-names>
            </name>
            <name>
              <surname>Murrell</surname>
              <given-names>DF</given-names>
            </name>
            <name>
              <surname>Joly</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Rituximab and its use in autoimmune bullous disorders</article-title>
          <source>Dermatol Clin</source>
          <year>2011</year>
          <volume>29</volume>
          <fpage>571</fpage>
          <lpage>575</lpage>
          <pub-id pub-id-type="pmid">21925000</pub-id>
        </element-citation>
      </ref>
      <ref id="B04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Arkfeld</surname>
              <given-names>DG</given-names>
            </name>
          </person-group>
          <article-title>The potential utility of B cell-directed biologic therapy in
autoimmune diseases</article-title>
          <source>Rheumatol Int</source>
          <year>2008</year>
          <volume>28</volume>
          <fpage>205</fpage>
          <lpage>215</lpage>
          <pub-id pub-id-type="pmid">17957371</pub-id>
        </element-citation>
      </ref>
      <ref id="B05">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mouquet</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Musette</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Gougeon</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Jacquot</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Lemercier</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Lim</surname>
              <given-names>A</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>B-cell depletion immunotherapy in pemphigus: effects on cellular and
humoral immune responses</article-title>
          <source>J Invest Dermatol</source>
          <year>2008</year>
          <volume>128</volume>
          <fpage>2859</fpage>
          <lpage>2869</lpage>
          <pub-id pub-id-type="pmid">18563177</pub-id>
        </element-citation>
      </ref>
      <ref id="B06">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cianchini</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Corona</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Frezzolini</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ruffelli</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Didona</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Puddu</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Treatment of Severe Pemphigus with Rituximab: report of 12 cases and a
review of the literature</article-title>
          <source>Arch Dermatol</source>
          <year>2007</year>
          <volume>143</volume>
          <fpage>1033</fpage>
          <lpage>1038</lpage>
          <pub-id pub-id-type="pmid">17709662</pub-id>
        </element-citation>
      </ref>
      <ref id="B07">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Matsukura</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Knowles</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Walsh</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Shear</surname>
              <given-names>NH</given-names>
            </name>
          </person-group>
          <article-title>Effect of a single-cycle alternative dosing regimen for rituximab for
recalcitrant pemphigus: a case series of 9 patients</article-title>
          <source>Arch Dermatol</source>
          <year>2012</year>
          <volume>148</volume>
          <fpage>734</fpage>
          <lpage>739</lpage>
          <pub-id pub-id-type="pmid">22351790</pub-id>
        </element-citation>
      </ref>
      <ref id="B08">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Joly</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Mouquet</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Roujeau</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>D'Incan</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gilbert</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Jacquot</surname>
              <given-names>S</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>A single cycle of rituximab for the treatment of severe
pemphigus</article-title>
          <source>N Engl J Med</source>
          <year>2007</year>
          <volume>357</volume>
          <fpage>545</fpage>
          <lpage>552</lpage>
          <pub-id pub-id-type="pmid">17687130</pub-id>
        </element-citation>
      </ref>
      <ref id="B09">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Diaz</surname>
              <given-names>LA</given-names>
            </name>
          </person-group>
          <article-title>Rituximab and pemphigus - a therapeutic advance</article-title>
          <source>N Engl J Med</source>
          <year>2007</year>
          <volume>357</volume>
          <fpage>545</fpage>
          <lpage>552</lpage>
          <pub-id pub-id-type="pmid">17687130</pub-id>
        </element-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hertl</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Eming</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Borradori</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Rituximab (anti-CD20 monoclonal antibody)--ultimate or first choice in
pemphigus?</article-title>
          <source>Dermatology</source>
          <year>2007</year>
          <volume>214</volume>
          <fpage>275</fpage>
          <lpage>277</lpage>
          <pub-id pub-id-type="pmid">17460396</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
